Affect Therapeutics

Affect Therapeutics

Signal active

Organization

Contact Information

Overview

Affect Therapeutics offers an integrated digital treatment program for drug and alcohol addiction via a mobile app. They provide treatments for a variety of substance use disorders. The program provides financial incentives to encourage healthy behaviors and new habits.

About

Industries

Health Care, Fitness, Wellness, Addiction Treatment

Founded

2020

Employees

51-100

Headquarters locations

New York, New York, United States, North America

Social

N/A

Profile Resume

Affect Therapeutics headquartered in New York, New York, United States, North America, operates in the Health Care, Fitness, Wellness, Addiction Treatment sector. The company focuses on Health Care and has secured $1.5B in funding across 64 round(s). With a team of 51-100 employees, Affect Therapeutics is actively contributing to advancements in Health Care. Their latest funding round, Series A - Affect Therapeutics, raised $16.0M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace Kristin Muhlner

Kristin Muhlner

Co-founder & CEO

imagePlace Russell Osborne

Russell Osborne

CTO

imagePlace Natalie Pitcher Clark

Natalie Pitcher Clark

Head Of Marketing

imagePlace Bryan Prout

Bryan Prout

Head of Member Services

Funding Rounds

Funding rounds

4

Investors

6

Lead Investors

0

Total Funding Amount

$23.0M

Details

4

Affect Therapeutics has raised a total of $23.0M in funding over 4 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2021Seed1.0M
2021Seed6.0M
2023Early Stage Venture
2023Early Stage Venture16.0M

Investors

Affect Therapeutics is funded by 22 investors.

Investor NameLead InvestorFunding RoundPartners
What If Ventures-FUNDING ROUND - What If Ventures16.0M
Imran Hamid-FUNDING ROUND - Imran Hamid16.0M
Affect Therapeutics-FUNDING ROUND - Affect Therapeutics16.0M
LifeArc Ventures-FUNDING ROUND - LifeArc Ventures16.0M

Recent Activity

There is no recent news or activity for this profile.